

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**Paper II – RADIATION AND MEDICAL ONCOLOGY IN
GYNAECOLOGIC CANCERS**

Q.P. Code: 181962

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Enumerate the criteria for diagnosis and Indications for chemotherapy in GTN. Give the revised FIGO scoring and elaborate management of Low risk Non metastatic GTN.
2. Explain in detail the Principles, technique, Indications, Contraindications, Efficacy and Complications of different types of Brachytherapy in Carcinoma cervix.

II. Write notes on:

(10 x 7 = 70)

1. Bragg's peak ad proton beam therapy.
2. Response evaluation criteria in solid tumors.
3. Radiation sensitizers.
4. Bevacizumab in carcinoma ovary.
5. Radiation tolerance of pelvic organs and complications of pelvic radiotherapy.
6. Liposomal doxorubicin.
7. Granulocyte stimulating therapy.
8. Chemotherapy induced nausea and vomiting.
9. Pressurised intraperitoneal aerosol chemotherapy in carcinoma ovary.
10. Intensity modulated Radiotherapy.

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**Paper II – RADIATION AND MEDICAL ONCOLOGY IN
GYNAECOLOGIC CANCERS**

Q.P. Code: 181962

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on: **(2 x 15 = 30)**

1. Discuss the use of external beam radiation for gynaecologic cancers.
2. Discuss the role of intraperitoneal chemotherapy in ovarian cancers.

II. Write notes on: **(10 x 7 = 70)**

1. Cellular response to radiation.
2. Computerised dosimetry.
3. Brachytherapy for endometrial cancer.
4. Interstitial applicators.
5. Radiation induced tissue effects.
6. Gompertzian tumour growth.
7. Chemotherapy principles.
8. Dose intensity and Dose density.
9. Gastrointestinal toxicity due to chemotherapy.
10. Carboplatin.

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**Paper II – RADIATION AND MEDICAL ONCOLOGY IN
GYNAECOLOGIC CANCERS**

Q.P. Code: 181962

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Describe the molecular targeted pathways and available targeted therapy in gynaecological malignancies.
2. Describe the role of radiation therapy in the management of endometrial cancer.

II. Write notes on:

(10 x 7 = 70)

1. Intensity Modulated and image guided radiotherapy in gynaecological cancer.
2. Role of conservative treatment in endometrial cancer.
3. Define febrile neutropenia. Enumerate the management and prevention strategies.
4. Metronomic chemotherapy in gynaecological cancer.
5. Radiotherapy and chemotherapy in positive groin and pelvic nodes in a patient with carcinoma vulva.
6. Side effect of pelvic radiation and measures to reduce the same.
7. What is the mechanism of chemoresistance? What is dose dense chemotherapy?
8. SOLO3 trial.
9. Role of Tamoxifen in gynaecological cancer.
10. Paclitaxel.

THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY

(MCH 0822)

AUGUST 2022

Sub. Code: 1962

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**Paper II – RADIATION AND MEDICAL ONCOLOGY IN
GYNAECOLOGIC CANCERS**

Q.P. Code: 181962

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on: **(2 x 15 = 30)**

1. Discuss the technique, pre operative preparations, procedure of heated intraperitoneal chemotherapy in ovarian cancer. Elaborate on the evidence in favour of HIPEC.
2. Discuss the role of image guided radiation therapy in cervical cancer. How is dose prescription done? Enumerate the benefits of IMRT versus conventional LINAC or Cobalt therapy.

II. Write notes on: **(10 x 7 = 70)**

1. WHO pain ladder.
2. Managements of platinum resistant ovarian cancer.
3. Total parenteral nutrition.
4. Methotrexate.
5. Immune checkpoint inhibitors.
6. Describe the isotopes used in brachytherapy.
7. Aromatase inhibitors in Gynecological cancers.
8. Management of febrile neutropenia.
9. SOLO 1 trial and beyond. Discuss the current recommendations.
10. Imiquimod.

THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY

(MCH 0124)

JANUARY 2024

Sub. Code: 1962

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**PAPER II – RADIATION AND MEDICAL ONCOLOGY IN
GYNAECOLOGIC CANCERS**

Q.P. Code: 181962

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Discuss external beam radiotherapy and its use in gynaecological malignancies.
2. Discuss the classification of chemotherapeutic agents and the use of chemotherapy in low risk GTN.

II. Write notes on:

(10 x 7 = 70)

1. Letrozole in gynaecological cancer.
2. Aurelia trial.
3. Computerised Dosimetry.
4. SOLO2 trial.
5. Role of hormonal therapy in endometrial cancer.
6. Liposomal doxorubicin.
7. Radiation induced short and long term complications.
8. Bevacizumab.
9. Chemotherapy in recurrent ovarian cancers.
10. Apoptosis.

THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY

(MCH 0225)

FEBRUARY 2025

Sub. Code: 1962

M.Ch. BRACH XII – GYNAECOLOGICAL ONCOLOGY

**PAPER II – RADIATION AND MEDICAL ONCOLOGY IN
GYNAECOLOGIC CANCERS**

Q.P. Code: 181962

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Discuss the role of radiation therapy in post operative endometrial cancer
2. First line therapy with PARP inhibitors in ovarian cancer. Discuss the evidence favoring this therapy, indications, dosage and side effects.

II. Write notes on:

(10 x 7 = 70)

1. Differentiate between basket and umbrella trials with examples.
2. Intraperitoneal chemotherapy.
3. Treatment of low risk GTN.
4. Carboplatin.
5. Febrile neutropenia.
6. Interstitial brachytherapy.
7. Metronomic chemotherapy.
8. Immunotherapy in cervical cancer.
9. Imiquimod.
10. Dose dense chemotherapy.

THE TAMIL NADU Dr. M.G.R. MEDICAL UNIVERSITY

(MCH 0126)

JANUARY 2026

Sub. Code: 1962

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**PAPER II – RADIATION AND MEDICAL ONCOLOGY
IN GYNAECOLOGIC CANCERS**

Q.P. Code: 181962

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Describe the various techniques of brachytherapy, what is the role of MRI in this treatment?
2. Management of recurrent and advanced stage endometrial cancer.

II. Write notes on:

(10 x 7 = 70)

1. Granulocyte colony stimulating factor.
2. Antiemetics in cancer chemotherapy.
3. INTERLACE trial.
4. Tamoxifen therapy in breast cancer.
5. Pembrolizumab.
6. Platinum resistant ovarian cancer.
7. PIPAC.
8. HRT in cancer survivors.
9. Use of VEGF inhibitors in Gynaecological cancers.
10. Neoadjuvant chemotherapy in cervical cancer.
